# Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer

> **NCT01671332** · PHASE2 · COMPLETED · sponsor: **University of Wisconsin, Madison** · enrollment: 80 (actual)

## Conditions studied

- Carcinoma, Non Small Cell Lung

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Suramin
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT01671332
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2015-06-11
- **Final completion:** 2016-06-16
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2020-05-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01671332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01671332, "Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01671332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*